Effects of remazolam on cognitive function, cellular immunity and stress response in frail elderly patients with gastrointestinal tumors through Wnt/ß-Catenin and Pl3K/AKT signaling pathways

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082875

Enrollment

Unknown

Registered

2024-04-10

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteric tumor

Interventions

Control group:Propofol General Anesthesia

Expiremental group:Remimazolam General Anesthesia

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 80 elderly patients undergoing tumor surgery were studied, and all patients were diagnosed with tumor. No surgical contraindications; People with normal communication skills and clear consciousness; Good treatment compliance; ASA Grade II- III.

Exclusion criteria

Exclusion criteria: Patients who refused to participate in the study, had severe heart, lung, and brain complications, severe diabetes, abnormal liver function and coagulation function, could not perform frailty assessment and MMSE score, and had incomplete clinical data.

Design outcomes

Primary

Measure	Time frame
T lymphoid subgroup( CD3+, CD4+,CD8+);Norepinephrine;Cognitive function;Epinephrine;The level of cortisol;CRP;IL-6;IL-8;PGE2;TNF-a;	—

Secondary

Measure	Time frame
Physical and Psychological condition indicators;VAS score;General situation;	—

Countries

China

Contacts

Public ContactZhu Xiaoning

People's Hospital of Ningxia Hui Autonomous Region

zxn0951@sina.com+86 138 9509 5081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026